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Background and Objectives: For over a decade, West Virginia’s (WV) rate of acute hepatitis B 
has been the highest in the United States (US). In 2017, WV’s rate was 11.7 per 100,000 
population, almost 12 times higher than the national rate. The increase in acute hepatitis B cases 
is largely due to substance misuse, including injection drug use (IDU). Hepatitis B is a vaccine 
preventable disease yet many at-risk adults remain unvaccinated and susceptible to infection. 
The objectives of our studies are to 1) describe yearly changes in acute hepatitis B incidence in 
WV and assess county-level impact of the WV Pilot Project using geospatial methods 2) assess 
hepatitis B vaccine dose completion by setting type in at-risk groups and 3) understand factors 
associated with hepatitis B virus (HBV) exposure in an emerging at-risk group of people who 
report using methamphetamine. 
Methods: Study 1. County rates of acute hepatitis B and vaccine doses per 100,000 population 
were visualized biannually from 2011 to 2018. Local indicators of spatial autocorrelation were 
used to detect county-level clustering. Significant differences in the median rate of acute 
hepatitis B pre and post intervention in counties receiving vaccine were evaluated using 
Wilcoxon signed-rank test and bootstrapping estimates. A Bland-Altman graph visualized 
significant differences in county-level rates of acute hepatitis B before and after the WV Pilot 
Project compared to the statewide estimate. Study 2. Deidentified data were collected from local 
health departments (LHDs) receiving hepatitis B vaccine through the WV Pilot Project and for 
which participant forms were available. The odds of receiving all three or at least two doses of 
hepatitis B vaccine were calculated using bivariate, multivariable, and mixed-effects regression 
models. Study 3. National Health and Nutrition Examination Survey data were utilized to 
examine factors associated with HBV exposure among participants who reported ever using 
methamphetamine using bivariate and multivariable logistic regression. 
Results: Study 1. Analyses identified significant geographic clustering of acute hepatitis B in 
southern WV across all four time-periods. Nine of the 18 (50%) counties receiving vaccine had 
significant declines in acute hepatitis B incidence compared to the statewide mean difference 
estimate. Study 2. Ten LHDs had data available representing 1,201 participants. In multivariable 
logistic regression, participants vaccinated at substance use treatment centers (aOR: 1.37; 95% 
CI: 1.01-1.86) and LHD family planning clinics (aOR: 3.74; 95% CI: 1.98-7.06) were more 
likely to receive the three-dose series compared to those vaccinated at LHD STD clinics. For the 
secondary outcome, participants vaccinated through substance use treatment centers (aOR: 1.79; 
95% CI: 1.31-2.44), correctional facilities (aOR: 3.34; 95% CI: 2.09-5.34), and LHD family 
planning clinics (aOR: 3.97; 95% CI: 1.72-9.16) were significantly more likely to receive at least 
two doses. Study 3. Overall, 847 participants representing approximately 11,048,115 people, met 
the study inclusion criteria. In multivariable logistic regression, female sex (aOR 3.83, 95% CI 
1.65 – 8.90), living below the poverty threshold (aOR 3.17, 95% CI 1.39 – 7.21), injection drug 
use (IDU) (aOR 4.89, 95% CI 1.95 – 12.26), active hepatitis C (HCV) infection (aOR 3.39, 95% 
CI 1.10 – 12.26), and identifying as men who have sex with men (aOR 28.21, 95% CI 5.19 – 
153.38) were significantly associated with HBV exposure. 
Conclusions: Despite the availability of a safe and effective hepatitis B vaccine, many 
individuals remain at risk of infection. Hepatitis B virus transmission continues in WV due in 
part to injection drug use and substance misuse. Ongoing efforts are needed to identify trends, 
guide testing and vaccination programs, and evaluate the effectiveness of those programs. 
Increased dissemination of hepatitis B vaccine through local health departments and existing 
harm reduction services can reduce the incidence of acute hepatitis B in states such as WV, 
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Hepatitis B is a liver disease resulting from infection with hepatitis B virus (HBV); a small 
partially double stranded DNA virus that infects humans [1]. The virus is spread through contact 
with blood and body fluids, is highly infectious, and environmentally stable; remaining viable on 
surfaces at room temperature for up to seven days [2]. HBV is estimated to be ten time more 
infectious than the hepatitis C virus (HCV) and one hundred times more infectious than human 
immunodeficiency virus (HIV) [3]. 
Infection with HBV results in an acute infection that may or may not be accompanied by signs 
and symptoms. Symptoms include fatigue, loss of appetite, nausea, vomiting, right upper 
quadrant pain, fever, headache, myalgia, dark urine, and jaundice [4, 5]. More than 85% of 
children and 50% of adults are asymptomatic [4]. The incubation period ranges from 45 days to 
160 days with an average of 90 days [6]. People acutely infected are able to transmit the virus 
one to two months before and after the onset of symptoms. About 1% of people acutely infected 
with HBV will develop fulminant hepatitis possibly resulting in death [7]. Acute infection can 
progress to a life-long chronic infection with age being the greatest factor in progression to 
chronicity [5, 8, 9]. Approximately, 90 to 95% of infants infected at birth will develop a chronic 
infection while only 5 to 10% of adults will progress to the chronic carrier state [9, 10]. About 
50% of people chronically infected are unaware of their infection and remain a source of on-
going transmission [11, 12].  
Hepatitis B virus infects liver cells resulting in chronic inflammation. Complications of chronic 
infection with HBV include cirrhosis, liver failure, hepatocellular carcinoma (HCC), and death 
[6, 10]. It is estimated that chronic infection is responsible for 50% of all cases of HCC and 25% 
of people with chronic infection will die prematurely from complications of the disease [11, 13]. 
There is no cure for hepatitis B, only treatment to slow the progression of disease.  
Hepatitis B is a significant public health problem worldwide. Almost 90% of the world’s 
population live in countries with either a high prevalence (greater than 8%) or intermediate 
prevalence (between 2% and 7%) of hepatitis B [14, 15]. Those living in high prevalence areas 
have a greater than 60% lifetime risk of acquiring hepatitis B while those living in an 
intermediate areas have a lifetime risk between 20% and 60% [14]. In countries with high or 
intermediate hepatitis B prevalence, most infections occur via vertical transmission during 
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childbirth or are acquired during childhood [16-18]. Estimates of the number of people 
chronically infected with HBV are as high as 350 million. The World Health Organization 
(WHO) estimates that globally approximately 3.5% of the world’s population (257 million 
people) are living with chronic HBV infections and an estimated 887,000 people died in 2015 as 
a result from disease complications [17, 19]. If current rates of hepatitis B remain unchanged, 20 
million people are projected to die from HBV related disease complications by 2030 [16]. Due to 
the global burden of all types of viral hepatitis, the WHO has developed a strategy to eliminate 
viral hepatitis as a public health threat by 2030 [16]. 
In the US, the incidence of acute hepatitis B infections has decreased 75% over the past three 
decades largely due to the implementation of universal vaccination of infants at birth in 1991 and 
recommendation of catch-up vaccination of adolescents in 1997 [20-22]. Despite decreases in the 
incidence of new infections, an estimated 800,000 to 2.2 million people are living with chronic 
infections [5, 23]. Estimates using National Health and Nutrition Survey (NHANES) data 
indicate the prevalence of chronic hepatitis B in the United States has remained around 0.3% 
since 1999 due in part to immigration of foreign-born persons from endemic countries [24]. 
Approximately, 70% of people chronically infected persons in the United States are foreign-born 
with nearly 50% of chronic infections occurring in non-Hispanic Asians [5, 23].  
Since 2006, the rate of acute HBV infections in the U.S. has remained stable at around 1 case per 
100,000 people [25, 26]. Major risk factors for acute HBV infection in the U.S. include injection 
drug use and multiple sexual partners [26]. Over the past decade, substance misuse has resulted 
in a resurgence in cases of acute hepatitis B in certain high-risk groups including people who 
inject drugs (PWID) [27, 28]. Nationwide, in 2015 the highest incidence of acute hepatitis B 
occurred among persons 30 to 39 years of age with 30% of newly infected people reporting IDU 
as a risk factor [28]. Most notably, there was a substantial increase in acute hepatitis B cases in 
parts of central Appalachia including Kentucky, Tennessee, and West Virginia (WV). From 
2009-2013, there was a 114% increase in the number of newly reported acute infections in these 
three states [25]. The majority of cases occurred among non-Hispanic whites, 30 to 39 years of 
age with 75% reporting IDU as a risk factor [25].  
PWID are at an increased risk of becoming infected with HBV through sharing of equipment to 
inject drugs and sexual contact [29]. Estimates of the non-institutionalized U.S. population 
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indicate that around 19.7% to 27.3% of PWID have serological lab markers consistent with past 
or present infection compared to just 4.6% of the general population [30, 31]. Adults with 
compromised immune systems are more likely to develop chronic infections and PWID may 
have a higher risk of developing chronic infection due to altered immune function and co-
infections with HCV and HIV [11, 32, 33]. Co-infections coupled with chronic drug use can 
result in increased morbidity and mortality as well as accelerated progression of liver disease 
[29]. Hepatitis B vaccination is recommended for PWID but despite this recommendation 
vaccination rates among PWID remains low [34]. Only an estimated 15% to 20% of PWID have 
lab markers consistent with vaccine-induced immunity compared to 23% to 30% of U.S. adults 
[31, 35, 36]. From 2003 to 2014, seroprevalence of vaccine-induced immunity increased in the 
general U.S. population but not in PWID, men who have sex with men (MSM), and people with 
chronic hepatitis C [35]. Low vaccination rates coupled with high-risk behaviors and reduced 
immune response to the vaccine means that many at-risk individuals remain vulnerable to 
acquiring HBV [32, 33].  
Rural areas have been disproportionately affected by the opioid crisis and disease transmission 
associated with IDU. An outbreak of HIV associated with IDU in rural Scott County prompted a 
nationwide county-level vulnerability of assessment to identify counties at high-risk for a similar 
outbreak [37, 38]. The assessment identified 220 counties in 26 states at risk for HIV and HCV 
transmission among PWID [38]. Twenty-eight of the 220 counties identified by the assessment 
were in WV, with two WV counties ranking in the top 10 (McDowell #2 and Mingo #7) [38]. 
Existing high rates of acute hepatitis B in WV coupled with vulnerability to outbreaks of 
infections associated with IDU, indicates the potential for ongoing transmission of HBV along 
with the risk of co-infections with HIV and HCV. 
Despite decreasing trends nationwide, the rate of new HBV infections in WV has steadily 
increased since 2002 (Figure 1) [39]. In 2016, WV’s rate of acute hepatitis B was 14.7 per 
100,000, almost 15 times the national average [40]. Since 2006, WV has ranked first in the 
nation with the highest rate of acute hepatitis B and either first or second for acute hepatitis C 
[26]. West Virginia rates of acute hepatitis B and hepatitis C have mirrored overdose mortality 
rates (Figure 2). From 2012-2016, the rate of acute hepatitis B cases was highest among males, 
persons 30 to 39, and cases were concentrated in the southern region of the state [41]. In 2016, 
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the most common risk factors reported in WV among people with acute hepatitis B was IDU or 
street drug use [42]. Given ongoing issues of substance misuse across WV, transmission of 
hepatitis B will continue among at-risk groups unless additional efforts are made to identify and 
prevent HBV infections in those with the highest risk of exposure. 
Along with opioid use, nationwide use of methamphetamine is rising due to an increase in the 
availability of cheaper, more potent methamphetamine flooding the US from Mexico [43, 44]. 
From 2010 to 2018, the number of methamphetamine seizures at the US border increased 
dramatically from 8,900 pounds to 82,000 respectively [44]. Methamphetamine use in the US 
peaked around 2005 but has reemerged as a threat in recent years [43, 45]. From 2011 to 2016, 
the number of overdose deaths involving methamphetamine more than tripled and accounted for 
11% of overdose deaths in 2016. Additionally, a recent study found methamphetamine use 
almost doubled from 18.8% in 2011 to 34.2% in 2017 among people using opioids who sought 
treatment in the US [46].  
Hepatitis B in people who use methamphetamine is not well described in the literature but its 
use, either through parenteral or non-parenteral routes, increases the risk for acquiring sexually 
transmitted infections including hepatitis B [47]. Recently, methamphetamine has been 
implicated in an increase in acute hepatitis B cases, as well as an increase in hepatitis C, HIV, 
and syphilis in the US and parts of Canada [48, 49]. In line with nationwide trends, overdose 
trends in WV suggest methamphetamine use is increasing across the state. In WV, the number of 
overdose deaths involving methamphetamine increased from 49 in 2015 to 323 in 2018 with 
36% of all overdose deaths in 2018 involving methamphetamine (Figure 3) [50, 51]. The 
increase in methamphetamine use and co-use with opioids represents a public health threat 
requiring a refocusing of response efforts in WV.    
Hepatitis B remains a real and ongoing threat to a number of at-risk groups, including people 
who use drugs and those engaging in high-risk sexual behaviors. It is recommended that at-risk 
people without serological evidence of HBV infection or immunity be vaccinated against HBV 
[27]. As substance misuse continues in WV, it is important to understand factors associated with 
HBV exposure among at-risk populations to help guide education, testing, and vaccination 
efforts.  
Purpose Statement:  
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The objectives of our studies are to describe yearly changes in acute hepatitis B incidence and 
assess county-level impact of the WV Pilot Project using geospatial methods, assess hepatitis B 
vaccine dose completion by setting type in at-risk groups, and understand factors associated with 
HBV exposure in an emerging at-risk group of people using methamphetamine. Study findings 
will contribute to knowledge about changes in the geographic distribution of hepatitis B in WV 
to help inform surveillance activities and placement of harm reduction services. Additionally, 
results will improve future vaccination programs and efforts among individuals at risk of HBV 
infection. 
Specific Aim 1. Use geospatial methods to examine changes in the distribution of acute hepatitis 
B in West Virginia in relation to counties participating in the WV Pilot Project. 
Purpose of Study 1. Despite having the highest rate of acute hepatitis B for over a decade, 
spatial trends in WV have not been examined over time. Visualizing trends and conducting 
cluster analyses can inform placement of harm reduction services, identify areas in need of 
enhanced surveillance, guide future vaccination efforts, and help evaluate the impact of 
interventions. Our study will incorporate a variety of geospatial methods to assess county-level 
distribution of acute hepatitis B rates before, during, and after the WV Pilot Project, identify 
county-level hotspots, and identify areas in need of additional hepatitis B prevention efforts.  
Specific Aim 2. Determine which setting type is associated with higher odds of completing all 
three or at least two doses of hepatitis B vaccine among at-risk individuals vaccinated through 
local health departments as part of a vaccine pilot project. 
Purpose of Study 2. Completion of the three-dose hepatitis B vaccination among at-risk adults 
remains a challenge. Despite WV’s participation in two federally funded hepatitis B vaccine 
initiatives (Adult Hepatitis B Vaccination Initiative, 2007–2009 and HepB Pilot Program, 2013-
2015), the effectiveness of such initiatives has not been evaluated. Our study will examine 
factors associated with completion of the three-dose hepatitis B vaccine in local health 
departments. Findings from this study will be valuable in informing future vaccination efforts 
among at-risk populations. There is a gap in the literature regarding strategies to increase 
hepatitis B vaccination in at-risk groups in rural areas. Given current drug misuse in Appalachia, 
this is an especially important and timely topic for both hepatitis A and B. 
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Specific Aim 3. Identify factors associated with HBV exposure among people who report using 
methamphetamine.  
Purpose of Study 3. People who use methamphetamine are at an increased risk of exposure 
from high-risk sexual behaviors and equipment used to administer the drug. Documented 
increases in reported methamphetamine use among people diagnosed with primary and 
secondary syphilis indicates there is an association between methamphetamine use and risky 
sexual behaviors [49]. Our study will examine factors associated with methamphetamine use and 



















Figure 1. Acute Hepatitis B Incidence Rate per 100,000 Population in West Virginia & United States, 1996 - 2017 
 













































Figure 2. Hepatitis B & Hepatitis C Incidence Rate per 100,000 Population & Age-adjusted Drug Overdose Mortality Rate per 
100,000 Population — West Virginia, 2007-2017 
 
*Age-Adjusted; Data sources: WV Office of Epidemiology and Prevention Services [52] , Centers for Disease Control and Prevention, Drug 

















































































Figure 3. Number of Fatal Drug Overdose Deaths and Select Substances — West Virginia, 2001-2018 
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The rate of acute hepatitis B in West Virginia (WV) has been increasing since 2006. To reduce 
new infections, WV implemented a vaccine intervention (WV Pilot Project), which provided 
over 10,000 doses of hepatitis B vaccine to at-risk adults in 18 counties. The objectives of this 
study were to describe yearly changes in acute hepatitis B incidence and assess county-level 
impact of the WV Pilot Project using geospatial methods. County rates of acute hepatitis B and 
vaccine doses per 100,000 population were visualized biannually from 2011 to 2018. Local 
indicators of spatial autocorrelation were used to detect county-level clustering. Significant 
differences in the median rate of acute hepatitis B pre and post intervention in counties receiving 
vaccine were evaluated using Wilcoxon signed-rank test and bootstrapping. A Bland-Altman 
graph visualized significant differences in county-level rates of acute hepatitis B before and after 
the WV Pilot Project compared to the statewide estimate. Analyses identified significant 
geographic clustering of acute hepatitis B in southern WV across all four time-periods. Nine of 
the 18 (50%) counties receiving vaccine had significant declines in acute hepatitis B incidence 
compared to the statewide mean difference estimate. Findings suggest that increased 
dissemination of hepatitis B vaccine through local health departments and existing harm 
reduction services can reduce the incidence of acute hepatitis B in states such as WV, which 
have been disproportionately affected by substance misuse.  










Hepatitis B is a liver disease resulting from infection with the hepatitis B virus (HBV). 
Complications of infection include fulminant hepatitis, cirrhosis, liver failure, hepatocellular 
carcinoma, and death [1]. The virus is spread through contact with blood and body fluids, is 
highly infectious, and environmentally stable on hard surfaces for more than seven days [2]. In 
the United States, major risk factors for infection include sexual exposure and injection drug use 
[3, 4]. People who inject drugs (PWID) are at an increased risk of acquiring hepatitis B 
infections through sharing of equipment to inject drugs and sexual contact [4, 5]. Estimates of 
the noninstitutionalized civilian United States population indicate that approximately 20 to 27% 
of PWID have lab markers consistent with past or present HBV infection compared to just 4.6% 
in the general population [6, 7].  
Over the past three decades, the incidence of new HBV infections in the United States has 
declined 75% due to universal vaccination of infants at birth, catchup vaccinations of 
adolescents, and human immunodeficiency virus (HIV) prevention efforts in men who have sex 
with men and PWID [8-10]. However, the increase in substance misuse and injection drug use 
over the past decade has resulted in a resurgence of acute cases of hepatitis B among at-risk 
groups especially in parts of Appalachia [4, 11, 12]. Despite the decreasing trend nationwide, the 
rate of acute HBV infections in West Virginia (WV) has steadily increased since 2006. In 2016, 
WV’s rate of acute HBV infections was 14.7 per 100,000 population, almost 15 times the 
national average of 1 per 100,000 population [10, 13]. Appalachian states, in particular 
Kentucky, Tennessee, and West Virginia, have been disproportionately affected by opioid 
misuse [12]. From 2009 to 2013, the three states reported a 114% increase in the number of 
reported acute hepatitis B cases [12]. The majority of these cases occurred in non-Hispanic 
whites, ages 30 to 39, with 75% of all cases reporting injection drug use as a risk factor [12]. 
From 2012 to 2016, injection and non-injection drug use were the two most commonly reported 
risk factors among people with acute hepatitis B in WV [13, 14] 
The CDC’s Advisory Committee on Immunization Practices (ACIP) currently recommends 
adults with risk factors, including recent or current injection drug use, receive hepatitis B 




In January 2013, the West Virginia Bureau for Public Health, Office of Epidemiology and 
Prevention Services (WV OEPS) initiated the West Virginia Hepatitis B Vaccination Pilot 
Program (WV Pilot Project), part of a larger CDC funded HepB Vaccine Pilot Program 
implemented in 14 local and state health departments nationwide [15]. The goal of the two-year 
project in WV was to decrease the number of new HBV infections by providing over 10,000 
doses of vaccine to at-risk adults in 18 counties with higher rates of acute hepatitis B [12, 16]. 
Vaccine was administered to adults considered at-risk for HBV infection at sites where universal 
HBV vaccination is recommended including HIV clinics, local health department (LHD) STD 
clinics, and LHD community partnerships with local substance use treatment centers and 
correctional facilities [15-17]. 
The objectives of this study were to describe yearly changes in county-level acute hepatitis B 
incidence and assess the impact of the WV Pilot Project using geospatial methods.  
METHODS 
For this retrospective study, 2011-2018 acute hepatitis B data and the number of HBV vaccine 
doses provided to WV Pilot Project counties were obtained from WV OEPS. Acute hepatitis B 
case counts by county are the result of cases identified through the Nationally Notifiable Disease 
Surveillance System and were limited to those meeting the CDC’s confirmed acute hepatitis B 
case definition; defined as “a case that meets the clinical case definition, is laboratory confirmed, 
and is not known to have chronic hepatitis B” [18]. Case data were incorporated into two-year 
estimated rates based on the years of vaccine distribution to counties participating in the WV 
Pilot Project; prior to vaccine distribution (2011-2012), during vaccine distribution (2013-2014 
and 2015 -2016), and following vaccine distribution (2017-2018). Geospatial methods, including 
mapping and cluster analyses, were used to examine changes in the distribution of acute hepatitis 
B in WV in relation to vaccination efforts. County rates were estimated in ArcMap 10.5.1 (ESRI 
Redlands, CA) using mid-year U.S. Census population estimates and joined to a WV counties 
shape file [19, 20]. Rate per 100,000 population of acute hepatitis B for each period were 
visualized using a quartile classification to highlight spread of the data, with darker colors 
indicating higher rates of acute hepatitis B. Vaccine doses per 100,000 population were 




population and multiplying by 100,000. The resulting rates were visualized using graduated 
symbols, with larger symbols indicating greater distribution of vaccine doses.  
Local Empirical Bayes Moran’s I and local indicators of spatial autocorrelation (LISA) maps 
were included to identify county-level acute hepatitis B clusters during each time-period using 
GeoDa 1.12 (GeoDa Center, AZ). To perform the cluster analyses, two-year case counts were set 
as the event variable, and midyear county-level census estimates were set as the base variable. A 
queen’s contiguity weight was specified to maximize neighbors involved and cluster analyses 
results were permuted 99999 times to increase robustness of analyses and identify statistically 
significant areas of high county-level acute hepatitis B rates [21]. Statistical significance was 
assessed at the 0.05 alpha level. The null hypothesis for the local cluster analysis was a random 
pattern of county-level rates of acute hepatitis B with no local spatial association [22].  
A Wilcoxon signed-rank test was used to detect a significant change in the median rate of acute 
hepatitis B per 100,000 population in WV Pilot Project counties before (2011-2014) and after 
(2015-2018) the intervention. Due to the small sample size of counties included in the analysis, 
bootstrapping was used to estimate the median rate change and 95% confidence interval, and to 
validate estimates from the Wilcoxon signed-rank test. A Bland-Altman graph, which plots the 
difference between two paired measurements against its mean, was used to visualize significant 
differences in county-level rates of acute hepatitis B per 100,000 population in all WV counties 
before and after the WV Pilot Project [23]. To assess statistical significance at the 0.05 alpha 
level, the statewide mean difference and corresponding 95% confidence interval (CI) were 
plotted. Counties with differences in rates of acute hepatitis B outside the upper or lower bounds 
of the 95% CI were considered significant. 
RESULTS 
County-level rates of acute hepatitis B per 100,000 population and the rate of vaccine doses per 
100,000 are displayed in Figure 1.1. Overall, rates of acute hepatitis B were highest in southern 
WV across the four time-periods. Zero case counts were present in 21 of 55 (38%) WV counties 
in 2012-2013, decreasing to 10 of 55 (18%) by 2017-2018. The highest rates of acute hepatitis B 
were observed in the southern counties, while the lowest rates were observed in northern 
counties. Over the four time-periods, progressive increases in rates of acute hepatitis B were 




to 4486.4, and were limited to 18 counties based upon population size and rates of acute hepatitis 
B. The rate of vaccine doses per 100,000 indicates the magnitude of vaccine doses distributed in 
relation to the county population with higher rates indicating a larger proportion of the 
population potentially receiving vaccine. 
County-level clustering in rates of acute hepatitis B in relation to vaccine doses per 100,000 
population are displayed in Figure 1.2. Analysis of county-level clustering takes into account 
rates in adjacent counties and identifies definite hotspots and coldspots or groups of counties 
(cluster) with high or low rates of acute hepatitis B. While counties in clusters changed 
somewhat over each time period, in general, hotspots (high-high clusters) indicating statistically 
significant clustering of high county-level rates of acute hepatitis B, were detected in southern 
WV during all time-periods (n=7 in 2011-2012, n=9 in 2013-2014, n=9 in 2015-2016, and n=8 in 
2017-2018). Over the four time-periods, the high-high clusters increased to include adjacent 
counties to the north and west, indicating progressive expansion into counties neighboring the 
initial multi-county hotspot. Of the nine counties identified in the 2013-2014 hotspot, seven 
(78%) received vaccine doses. Cold spots (low-low clusters) indicating statistically significant 
clustering of low county-level rates of acute hepatitis B, were detected in northern and eastern 
WV counties during all time-periods (n=10 in 2011-2012, n=9 in 2013-2014, n=10 in 2015-
2016, and n=9 in 2017-2018).  
The median hepatitis B rate difference before and after the WV Pilot Project (calculated using 
the Wilcoxon signed-rank test and bootstrapping) for participating counties was an increase of 
1.21 per 100,000 population (95% CI, -13.29, 21.93) following the intervention, however the 
increase was not significant (p-value = 0.90). Due to the small sample size of WV Pilot Project 
counties included in the analysis (n=18), bootstrapping was used to estimate the median rate 
difference along with a 95% CI. This resulted in a median rate decrease of -4.16 of acute 
hepatitis B cases per 100,000 population (95% CI, -33.07, 19.36) following the intervention. The 
Bland-Altman mean difference analysis found  the statewide mean difference before and after 
the intervention was an increase of 10.80 cases per 100,000 population (95% CI, 0.80, 20.79). 
County-level differences in rates of acute hepatitis B before and after the WV Pilot Project and 
the statewide mean difference and 95% CI are displayed in Figure 1.3. Twelve of the 18 WV 




reduction in the rate of acute hepatitis B following vaccine distribution compared to the 
statewide mean difference. Of these, nine (50%) had statistically significant declines as indicated 
by a rate difference below the lower bound of the statewide 95% CI. However, four (22%) of the 
18 WV Pilot Project counties had statistically significant increases in rates of acute hepatitis B 
following the intervention compared to the statewide mean difference. Of the 37 non-Pilot 
Project counties, 8 (22%) experienced a statistically significant decrease and 11 (30%) a 
statistically significant increase as indicated by values below and above the 95% CI respectively.  
DISCUSSION 
In this study, we found the incidence rate of acute hepatitis B increased steadily across WV with 
rates peaking in 2015-2016 and then slightly declining in 2017-2018. One of the most notable 
findings of this study was the shift in counties identified as hotspots through cluster analyses 
across the four time-periods. This shift suggests counties at risk for HBV transmission are 
changing and additional efforts are needed in emerging hotspots. Two counties identified as 
hotspots in all four time-periods did not receive vaccine through the WV Pilot Project 
demonstrating a missed opportunity to vaccinate at-risk individuals. All counties identified as a 
hotspot in the 2017-2018 cluster analysis may benefit from enhanced hepatitis B surveillance and 
increased efforts to prevent new HBV infections.  
While the median difference calculated using both the Wilcoxon signed-rank test and 
bootstrapping estimates found non-statistically significant changes in the median rate of acute 
hepatitis B in Pilot Project counties, the median difference estimate obtained via bootstrapping 
indicates a decrease of 4.16 cases per 100,000 population (95% CI, -33.07, 19.36) after WV Pilot 
Project implementation. Due to the small sample size of counties included in the analysis, the 
bootstrapping estimate most likely provides a better approximation compared to the estimate 
obtained from the Wilcoxon signed-rank test. 
Another notable finding was the significant decrease in the rate difference before and after the 
WV Pilot Project (as indicated by values below the statewide mean difference 95% CI)  in nine 
participating counties – Berkeley, Hancock, Harrison, Jefferson, Mason, McDowell, Mercer, 
Mingo, and Wyoming. While eight of the 37 (22%) non-Pilot Project counties experienced a 
similar decrease, a significant decrease was observed in 50% of WV Pilot Project counties. 




infections in at-risk adults especially in the southern part of WV where the greatest acute 
hepatitis B rate differences were observed. In total, 12 of the 18 WV Pilot Project counties had 
acute hepatitis B rate differences below the WV mean difference and while not all of the results 
were statistically significant, these findings point to the effectiveness of the WV Pilot Project in 
reducing or stabilizing rates in these counties.  
From 2013 to 2015, the WV Pilot Project administered over 10,000 doses of HBV vaccine to 
adults considered at risk for HBV infection in 18 counties. At-risk adults were reached through 
local health department STD clinics, correctional facilities, substance use treatment centers, and 
HIV care facilities [15, 16]. Completion of the three-dose series was cited as a challenge 
throughout the project [16]. In WV, of those who initiated the vaccine series, 59% received the 
second dose, and 32% completed the three-dose series [16]. Although some protection is 
conferred through receipt of one or two doses of hepatitis B vaccine, people who use drugs may 
have an altered immune response and therefore less likely to be protected after receiving just one 
or two doses [24]. Failure to complete the series, coupled with lower immune response may have 
resulted in less at-risk individuals protected against HBV infection, thus reducing the impact of 
the WV Pilot Project. 
Strength and Limitations 
Strengths of this study include the use of geospatial modeling, including cluster analyses, to 
examine trends in acute hepatitis B over eight years in WV. Hotspots identified in the cluster 
analyses indicate a statistically significant high county rate of acute hepatitis B in relation to the 
surrounding counties representing a non-random pattern. Another strength is the use of 
bootstrapping, which provides a better approximation of the median pre and post intervention 
due to the small sample size of counties included in the estimation. Finally, the use of Bland-
Altman analysis to calculate and plot the difference in rates of acute hepatitis B before and after 
the WV Pilot Project for comparison with the statewide mean difference and 95% CI, provides a 
method to assess if the rate differences for individual counties were statistically significant. 
Potential limitations of this study include a lack of county-specific data regarding the number of 
participants who completed vaccination through the WV Pilot Project. However, vaccine doses 
per 100,000 population in each county is an indication of the volume of vaccine distributed in 




completed the series developed immunity as post-serological testing was either not done or data 
were not available. Previous studies have shown that immune response to hepatitis B vaccine is 
lower in people with altered immune function including PWID, so not everyone vaccinated may 
have developed immunity [24]. Additionally, the 2018 acute hepatitis B case counts from WV 
OEPS used in all calculations were provisional and thus subject to change. Forty-four of the 55 
WV counties have populations under 55,000 making the rates easily influenced by small case 
counts. Combined time-periods were used in order to stabilize rates, but small counties were still 
subject to large rates based on few cases of acute hepatitis B. Finally, many factors may have 
resulted in either an increase or decrease in the incidence rates of acute hepatitis B infections 
between the time-periods therefore making it difficult to determine the overall impact the WV 
Pilot Project on incidence rates. The first WV harm reduction program with syringe exchange 
opened in 2015 after the WV Pilot Project, and in 2017 there were 12 such programs [25]. 
Overall efforts to reduce the effects of substance misuse in WV may have reduced the number of 
new acute hepatitis B infections. However, to our knowledge there have been no new statewide 
hepatitis B vaccine initiatives since the WV Pilot Project. 
CONCLUSION 
Hepatitis B is a vaccine preventable disease, yet many at-risk adults remain unvaccinated and 
susceptible to infection. Ongoing harm reductions efforts, including syringe exchange programs, 
STD clinics, and LHD partnerships with community programs serving at-risk adults, should 
incorporate hepatitis B testing and vaccination to reduce the number of new HBV infections. 
Geographic information systems can guide surveillance efforts, placement of prevention 
services, and direct future interventions by identifying trends and changes in new HBV 
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Figure 1.1 West Virginia county-level rates of acute hepatitis B from 2011 through 2018 and 
vaccine doses per 100,000 population. Darker colors and larger circles indicate a higher rate of 
acute hepatitis B and vaccine doses per 100,000 population respectively.  
 




Figure 1.2 West Virginia acute hepatitis B cluster analyses and vaccine doses per 100,000 
population. High-high counties, depicted in black, are hotspots or a group of counties with high 
rates of acute hepatitis B. Low-low counties, depicted in dark grey, are coldspots or a group of 
counties with low rates of acute hepatitis B. High-low and low-high counties are spatial outliers 
indicating a county with a high rate surrounded by counties with low rates or a county with a low 
rate surrounded by counties with high rates of acute hepatitis B. 
 




Figure 1.3 Bland-Altman graph depicting the difference in acute hepatitis B rates per 100,000 population in WV Pilot Project and non-
Pilot Project counties compared to the mean difference for all of West Virginia before and after WV Pilot Project implementation. 
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Variations in Hepatitis B Vaccine Series Completion by Setting among  
At-Risk Adults in West Virginia 
ABSTRACT 
Introduction: West Virginia (WV) leads the nation with the highest rate of acute hepatitis B. 
From 2013 to 2015, the West Virginia Hepatitis B Vaccination Pilot Project (WV Pilot Project) 
distributed over 10,000 doses of hepatitis B vaccine through local health department (LHD) 
clinics and through LHD outreach to correctional facilities and substance use treatment centers to 
at-risk adults. The objectives of this study were to determine which setting type was associated 
with the greatest likelihood of receiving all three or at least two doses of hepatitis B vaccine. 
Methods: Data for this retrospective cohort study were accessed, extracted, and analyzed in 2019 
from WV Pilot Project participant forms initially completed from 2013 to 2015. The odds of 
receiving all three or at least two doses were calculated using bivariate, multivariable, and 
mixed-effects regression models.  
Results: Data were available for 1,201 participants. In multivariable logistic regression, 
participants vaccinated at substance use treatment centers (aOR: 1.37; 95% CI: 1.01-1.86) and 
LHD family planning clinics (aOR: 3.74; 95% CI: 1.98-7.06) were more likely to receive the 
three-dose series compared to those vaccinated at LHD STD clinics. For the secondary outcome, 
participants vaccinated through substance use treatment centers (aOR: 1.79; 95% CI: 1.31-2.44), 
correctional facilities (aOR: 3.34; 95% CI: 2.09-5.34), and LHD family planning clinics (aOR: 
3.97; 95% CI: 1.72-9.16) were more likely to receive at least two doses. 
Conclusion: Hepatitis B vaccination delivered at LHD family planning clinics, substance use 






West Virginia (WV) has been disproportionately affected by the opioid crisis resulting in 
increased rates of acute hepatitis B [1-3]. For over a decade, WV’s rate of acute hepatitis B has 
been the highest in the United States (U.S.) [1, 2].  In 2017, WV’s rate was 11.7 per 100,000, 
almost 12 times higher than the national rate [1, 2]. This increase in acute hepatitis B virus 
(HBV) infections is largely due to substance misuse, including injection drug use (IDU) [2, 3]. 
From 2012 to 2015, the Centers for Disease Control and Prevention (CDC) funded a vaccine 
pilot program in 14 state and local health departments, including WV, to reduce the number of 
new HBV infections in at-risk adults [4]. Adults were vaccinated in settings where universal 
vaccination is recommended, and in specific settings where those with risk factors are typically 
seen or who were living in communities with an increased incidence of acute hepatitis B [4, 5]. 
As part of the national pilot program, the West Virginia Hepatitis B Vaccination Pilot Program 
(WV Pilot Project) distributed over 10,000 doses of HBV vaccine to the 18 counties with higher 
rates of acute HBV [6]. Eighteen WV local health departments (LHDs) vaccinated at-risk adults 
in their own STD, family planning, vaccine, and other clinics as well as through expanded 
outreach to correctional facilities and substance use treatment centers through vaccine delivery 
partnerships.  
The objectives of this study were to determine which setting type was associated with the 
greatest likelihood of receiving all three doses (primary objective) or at least two doses 
(secondary objective) of the three-dose HBV vaccine series among WV Pilot Project participants 
vaccinated through WV LHDs. Receipt of at least two doses of vaccine was chosen as the 
secondary objective for two reasons. First, some protective antibody response is conferred from 





achieving anti-HBs ≥ 10 mIU/mL after receiving two doses [5, 7, 8]. Second, in 2017, the FDA 
approved a new two-dose, HBV vaccine called Heplisav-B that can be completed in just four 
weeks compared to the minimum of 16 weeks needed to complete the traditional 3-dose series 
[9, 10]. Therefore, understanding which sites were associated with completion of at least two 
doses of HBV vaccine has implications for future vaccination efforts using either the traditional 
3-dose series or the new 2-dose Heplisav-B vaccine. 
METHODS 
Deidentified data for this retrospective cohort study were accessed in 2019 from LHDs that 
participated in the WV Pilot Project and extracted from available participant forms previously 
completed from January 2013 through September 2015. This study was approved by the West 
Virginia University Institutional Review Board. 
Local health departments participating in the WV Pilot Project were contacted and invited to 
participate in the study. Participants were eligible for inclusion in the study if they received at 
least one dose of vaccine through the WV Pilot Project through a LHD; had not previously 
started the HBV vaccine series elsewhere; were negative for all HBV lab markers if tested; were 
not vaccinated at multiple settings; and had available data for both the main exposure variables 
and vaccine dosage administration. A flow chart detailing inclusion criteria for the final sample 
selection can be found in Figure 2.1. The three participating clinics serving persons with HIV 
were not included in this study. 
Outcome variables 
The outcome for the primary objective, completion of the three-dose HBV vaccine series, was 





between doses one and two, at least eight weeks between doses two and three, and a minimum of 
at least 16 weeks between doses one and three [11, 12]. Non-completion for the primary outcome 
was defined as receiving one or two doses. The outcome for the secondary objective was defined 
as receiving two doses of the three-dose HBV vaccine series; non-completion was defined as 
receiving only one dose. 
Exposure variables 
The primary exposure variable, setting type, was restricted to the setting options available to 
LHDs on the participant form. These included STD and other clinics located at LHDs, and LHD 
outreach to correctional facilities and substance use treatment centers. Local health department 
‘other clinics’ included participants vaccinated at any on-site LHD clinic other than the STD 
clinic. A separate ‘LHD family planning’ category was derived from the ‘other clinics’ category 
due to the number of participants who were vaccinated at this setting. Participants vaccinated 
through ‘other clinics,’ including family planning, were required to have a risk factor. However, 
people could state they did not wish to answer the risk factor information but would still like to 
be vaccinated against hepatitis B. Due to differences among LHDs in coding for correctional 
facilities and substance use centers, the two categories were standardized according to the 
following criteria: settings that included regional jails, drug courts, and day report centers were 
coded as ‘correctional facility’, and inpatient and outpatient drug treatment facilities, methadone 
and buprenorphine clinics were coded as ‘substance use treatment center.’ Additional exposure 
variables included sex, age, and race. Age was categorized as 18-29, 30-39, 40-49, and 50+ years 
old. Race was categorized as ‘African American’ or ‘white/other/missing’ due to the majority of 







Analyses were completed in 2019. SAS version 9.4 was used for all analyses with α set to 0.05. 
Missing data were treated with pairwise deletion. Frequencies and percentages were calculated 
for all exposure variables and both the primary and secondary outcomes. A Chi-squared test was 
used to assess for significant relationships between the exposure variables and the outcomes. 
Unadjusted odds ratios (uOR) with accompanying 95% Confidence Intervals (CI) were 
calculated using bivariate logistic regressions with logit link and standard selection. 
Multivariable logistic regressions were used to calculate the adjusted odds ratios (aOR) with 
accompanying 95% CIs for the main exposure variable and primary and secondary outcomes 
controlling for sex, age, and race. Mixed-effects generalized linear regression models 
(GLIMMIX) were used to account for the random effects of participants nested within LHDs. 
Exposure variables from the bivariate and multivariable models were included in the GLIMMIX 
models.  
In this study, ORs are reported in lieu of risk ratios (RR) due to the convergence problems when 
estimating relative risk with the complex mixed-effects models. To assess for the possibility of 
the ORs overestimating the strength of association, a sensitivity analysis was conducted using 
unadjusted and adjusted RRs and accompanying 95% CIs using generalized linear (GENMOD) 
models.  
RESULTS 
Eighteen LHDs received vaccine through the WV Pilot Project, of which 10 LHDs, representing 
counties from across the state, had participant forms available for inclusion in the study. A total 





Of the 1,428 participants, 191 started the series at a location other than the LHD or were fully 
immunized per immunization records, 24 had lab results consistent with past or present HBV 
infection, and 12 were vaccinated at multiple sites or their forms could not be located. Overall, 
1,201 participants met the inclusion criteria and were included in the analyses with the number of 
study eligible participants vaccinated through each LHD ranging from 26 to 441. (Figure 2.1 & 
Supplementary Table 2.1).  
A description of the number of participants vaccinated through each of the ten LHDs by setting 
type can be found in Supplementary Table 2.1. Nine LHDs vaccinated participants through their 
on-site STD clinics, eight vaccinated participants in ‘other’ on-site LHD clinics, and two 
vaccinated women through on-site LHD family planning clinics. Half of the LHDs vaccinated 
participants through partnerships with local substance use treatment centers and six collaborated 
with local correctional facilities.  
The majority of participants were vaccinated through LHD STD clinics (46%) or LHD outreach 
to substance use treatment centers (27.6%) (Table 2.1). Over half were male (54.5%) and most 
self-identified their race as white (85%). Approximately three-quarters of participants were 
between 18 and 39 years of age with almost equal numbers in the 18 to 29 (37%) and 30 to 39 
(36.7%) age groups.  
Thirty-six percent of participants received all three doses of the HBV vaccine series and 64.4% 
received at least two doses (Supplementary Table 2.2). While the majority were vaccinated at 
LHD STD clinics (46%), the highest percentage of three-dose completion occurred among those 
vaccinated at LHD family planning clinics (63.3%) and through LHD outreach to substance use 





doses were documented at LHD family planning clinics (85.7%), correctional facilities (80.9%), 
and substance use treatment centers (72%). 
Primary and Secondary Objectives, Unadjusted  
For the primary objective, participants vaccinated at substance use treatment centers (uOR: 1.34; 
95% CI: 1.02-1.78) and LHD family planning clinics (uOR: 3.25; 95% CI: 1.77-5.97) were 
significantly more likely to complete the three-dose HBV vaccine series compared to those 
vaccinated at LHD STD clinics (Table 2.2). Participants vaccinated through other LHD clinics 
(uOR: 0.53; 95% CI: 0.34-0.82) were significantly less likely to receive three doses. Women 
(uOR: 1.43; 95% CI: 1.13-1.81) and participants ages 30 to 39 (uOR: 1.34; 95% CI: 1.01-1.78), 
40 to 49 (uOR: 2.13; 95% CI: 1.48-3.08), and 50 and older (uOR: 2.21; 95% CI: 1.50-3.24) were 
all significantly more likely to complete the three-dose series.  
For the secondary objective, participants vaccinated at substance use treatment centers (uOR: 
1.90; 95% CI: 1.42-2.55), correctional facilities (uOR: 3.12; 95% CI: 1.98-4.91), and LHD 
family planning clinics (uOR: 4.43; 95% CI: 1.96-10.04) were all significantly more likely to 
receive at least two doses of HBV vaccine compared to those vaccinated at LHD STD clinics. 
Again, women (uOR: 1.37; 95% CI: 1.08-1.75) were significantly more likely to receive at least 
two doses while participants self-identifying as African American (uOR: 0.82; 95% CI: 0.69-
0.98) were less likely to receive at least two doses. 
Primary and Secondary Objectives, Adjusted 
In the multivariable logistic regression model, after controlling for sex, age, and race, 
participants vaccinated at substance use treatment centers (aOR: 1.37; 95% CI: 1.01-1.86) and 





three-dose series while those vaccinated at other LHD clinics (aOR: 0.38; 95% CI: 0.23-0.61) 
were significantly less likely to complete the three-dose series (Table 2.3). In this model, older 
age remained significantly associated with three-dose completion.  
For the secondary outcome, participants vaccinated through substance use treatment centers 
(aOR: 1.79; 95% CI: 1.31-2.44), correctional facilities (aOR: 3.34; 95% CI: 2.09-5.34), and LHD 
family planning clinics (aOR: 3.97; 95% CI: 1.72-9.16) were significantly more likely to receive 
at least two doses. Once again, women (aOR: 1.44; 95% CI: 1.11-1.86) and participants ages 50 
and older (aOR: 1.83; 95% CI: 1.20-2.78) were also more likely to receive at least two doses in 
the full model.  
Primary and Secondary Objectives, Adjusted and Controlling for LHD 
In the mixed-effects model, after controlling for the LHD as a random effect and sex, age, and 
race as fixed effects, participants vaccinated at substance use treatment centers (aOR: 1.73; 95% 
CI: 1.20-2.50) and LHD family planning clinics (aOR: 3.51; 95% CI: 1.63-7.56) were 
significantly more likely to receive three doses compared to those vaccinated at LHD STD 
clinics (Supplementary Table 2.3). In this model, older age remained significantly associated 
with three-dose completion. 
For the secondary objective, participants vaccinated at substance use treatment centers (aOR: 
2.12; 95% CI: 1.46-3.09), correctional facilities (aOR: 2.94; 95% CI: 1.74-4.96), and LHD 
family planning clinics (aOR: 4.88; 95% CI: 1.87-12.72) were significantly more likely to 
receive at least two doses of HBV vaccine. Women (aOR: 1.51; 95% CI: 1.11-2.06) and 
participants ages 50 and older (aOR: 1.88; 95% CI: 1.18-3.01) were also significantly more 






Unadjusted and adjusted RR estimates were compared with the calculated OR. In general, the 
OR closely approximated the RR. Given the OR and RR gave similar results that remained 
significant across both estimates, the OR were deemed an acceptable measure of association for 
this retrospective cohort study. 
DISCUSSION 
This is the first study to evaluate the impact of setting on completion of the HBV vaccine series 
among at-risk individuals vaccinated through WV LHDs, either at their own clinics or through 
expanded vaccine delivery partnerships in locations serving at-risk adults. In this study, we 
found LHD family planning clinics and LHD outreach to substance use treatment centers were 
associated with increased odds of receiving all three doses as well at least two doses of HBV 
vaccine compared to LHD STD clinics. Additionally, participants vaccinated through LHD 
outreach to correctional facilities were more likely to receive at least two doses. Differences in 
receiving either two or three doses between sites most likely reflects the vaccine delivery setting 
and the potential for continued future interactions with participants. People attending LHD STD 
clinics may only have a single visit, while women attending a family planning clinic are likely to 
return at least once a year or more. Substance use treatment centers and correctional facilities are 
also settings where clients are likely to have sustained interactions with program staff. 
Both in WV and nationally the greatest number of participants were reached through STD 
clinics, but the proportion of participants receiving all three doses were low [4]. While STD 
clinics provide a way to initiate the HBV vaccine series in many at-risk adults, series completion 





information systems can potentially generate automatic reminders and flag client charts so staff 
can contact individuals for return visits to complete the vaccine series.  
In 2016, the three most common risk factors among people with acute HBV infection in WV 
were injection drug use, street drug use, and incarceration [13]. The percentage of participants 
receiving at least two doses through LHD outreach at correctional facilities including drug court 
(81%) and substance use treatment centers (72%) indicates that ongoing LHD partnerships with 
these settings might facilitate their ability to reach more at-risk individuals who need hepatitis B 
vaccination due to a history of substance misuse or injection drug use. Harm reduction programs 
across the state also provide another venue to reach these high-risk individuals. LHDs manage 
the majority of harm reduction programs in WV: the first LHD syringe services program opened 
in late 2015 and as of 2020, 16 LHDs offer harm reduction services including testing for IDU-
related infections and HBV vaccination [14]. Given the risk factors for acute HBV infection in 
WV, targeting HBV vaccination efforts through substance use treatment centers, correctional 
facilities, and harm reduction programs, in conjunction with use of the new two-dose Heplisav-B 
vaccine, would provide protection to a greater number of those with the highest risk of hepatitis 
B in a shorter period.  
A notable finding of this study is that women were significantly more likely to receive all three 
and just two doses compared to men. This, in combination with the increased odds of completion 
among family planning clinic participants, has important implications for preventing new 
hepatitis B infections in women of reproductive age. A recent study using national data from 
Quest Laboratories found a significant increase in the number of reproductive age women in WV 
testing positive for anti-HBc, a marker of past or current HBV infection [15]. Although the odds 





number of women reached was relatively small compared to other settings. Future vaccination 
efforts should include screening LHD family planning participants for hepatitis B risk factors. 
Women with risk factors, or those requesting STD screening as part of their family planning 
appointment, should be offered testing and vaccination.  
Overall, completion of the second and third doses were higher in WV compared to other CDC 
awardees. In WV, of those who received the first dose, 59% received the second dose, and 32% 
received all three doses [4]. Completion of the second and third doses for the six primarily urban 
CDC Pilot Program awardees with available data were 40% and 22% respectively [4]. The 
success of the WV Pilot Project may be due in part to the important role LHDs play in rural 
communities where healthcare access is limited. However, due to limited staff and associated 
vaccine/program costs, the WV LHDs were unable to sustain the WV Pilot Project activities 
after its conclusion in 2015. Expansion of Medicaid through the Affordable Care Act, along with 
the increased ability of LHDs to bill for services, may allow for provision of testing and HBV 
vaccination without additional cost to the client or LHDs in West Virginia.  
Potential limitations 
Both a strength and a limitation of this study is the inclusion of participant level data from ten of 
the 18 LHDs participating in the WV Pilot Project. The ten LHDs included counties from across 
the state, thus increasing the generalizability of findings; on the other hand, despite broad 
geographic representation, data were only available for 56% of the participating LHDs. Another 
potential limitation of this study is that data were not collected for research purposes, and the 
quality of the data varied among sites. To help overcome this limitation, settings where vaccine 
was administered were standardized across the LHDs, but there is still potential for 






The WV Pilot Project provided over 10,000 doses of HBV vaccine to adults considered at risk of 
hepatitis B infection. Targeting vaccine delivery in settings outside of the LHD STD clinic may 
increase vaccine dose completion in WV, thus resulting in more at-risk adults protected against 
HBV infection. Given that substance misuse and incarceration are the most common risk factors 
among people with acute HBV infection in WV, future LHD hepatitis B vaccine interventions 
should prioritize testing and vaccinating in settings serving high-risk adults including substance 
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773 (64.4) 428 (35.6) 
 
Setting type 
       
LHD - STD 
clinic 




<0.001 314 (57.5) 232 (42.5) <0.001 
LHD outreach to 
substance use 
treatment center 





239 (72.0) 93 (28.0) 
 
LHD outreach to 
correctional  
facility 





114 (80.9) 27 (19.1) 
 
LHD - other 
clinicc 





64 (48.1) 69 (51.9) 
 
LHD - family 
planning clinic 





42 (85.7) 7 (14.3) 
 
        
Sex 
       




0.003 400 (61.1) 255 (38.9) 0.009 





373 (68.3) 173 (31.7) 
 
        
Age 
       




<0.001 267 (60.3) 176 (39.7) 0.172 
















113 (67.3) 55 (32.7) 
 





97 (66.4) 49 (33.6) 
 
        
Race 
       
White, missing, 
& other 




0.55 715 (65.4) 378 (34.6) 0.015 
African 
American 





58 (53.7) 50 (46.3) 
 
a Outcome variables are reported as the percentage relative to the row attribute 2 
b p-value for Chi-squared test statistic. Abbreviations: STD =sexually transmitted disease; LHD = local health department 3 
c Includes participants vaccinated in LHD clinics other than STD and family planning 4 




Table 2.2. Unadjusted odds ratios for exposure variables and primary and secondary objectives 
 Primary objective Secondary objective  
Received 3 doses Received at least 2 doses 
Variable uOR 95% CI p-value uOR 95% CI p-value 
Setting type 
      




LHD outreach to substance 
use treatment center 
1.34 (1.02-1.78) 0.039 1.90 (1.42-2.55) <0.001 
LHD outreach to 
correctional  
facility 
0.89 (0.60-1.32) 0.547 3.12 (1.98-4.91) <0.001 
LHD - other clinica 0.53 (0.34-0.82) 0.005 0.69 (0.47-1.00) 0.05 
LHD - family planning 
clinic 
3.25 (1.77-5.97) <0.001 4.43 (1.96-10.04) <0.001 
       
Sex 





Female 1.43 (1.13-1.81) 0.003 1.37 (1.08-1.75) 0.009        
Age 
      




30-39 yrs 1.34 (1.01-1.78) 0.042 1.31 (1.00-1.72) 0.055 
40-49 yrs 2.13 (1.48-3.08) <0.001 1.35 (0.93-1.97) 0.112 
50+ 2.21 (1.50-3.24) <0.001 1.31 (0.88-1.93) 0.184        
Race 
      




African American 0.88 (0.58-1.34) 0.549 0.61 (0.41-0.91) 0.016 
Abbreviations: STD =sexually transmitted disease; LHD = local health department. 
a Includes participants vaccinated in LHD clinics other than STD and family planning 












Table 2.3. Adjusted odds ratios for exposure variables and primary and secondary objectives  
 Primary outcome Secondary outcome  
Received 3 doses Received at least 2 doses 
Variable aOR 95% CI p-value aOR 95% CI p-value 
Setting type 
      




LHD outreach to 
substance use treatment 
center 
1.37 (1.01-1.86) 0.041 1.79 (1.31-2.44) <0.001 
LHD outreach to 
correctional  
facility 
0.91 (0.60-1.39) 0.6622 3.34 (2.09-5.34) <0.001 
LHD - other clinica 0.38 (0.23-0.61) <0.001 0.58 (0.39-0.87) 0.008 
LHD - family planning 
clinic 
3.74 (1.98-7.06) <0.001 3.97 (1.72-9.16) 0.001 
       
Sex 





Female 1.28 (0.98-1.66) 0.069 1.44 (1.11-1.86) 0.006        
Age 
      




30-39 yrs 1.40 (1.04-1.89) 0.027 1.21 (0.91-1.62) 0.196 
40-49 yrs 2.57 (1.76-3.77) <0.001 1.39 (0.94-2.05) 0.102 
50+ 3.38 (2.23-5.13) <0.001 1.83 (1.20-2.78) 0.005        
Race 
      
White, missing, & other 1 
     
African American 0.92 (0.59-1.44) 0.729 0.78 (0.52-1.19) 0.254 
Abbreviations: STD =sexually transmitted disease; LHD = local health department. 
a Includes participants vaccinated in LHD clinics other than STD and family planning 









Supplementary Table 2.1. Number of WV Pilot Project participants vaccinated through each 

























1 194 157 90 - - 441 
2 86 60 - 36 6 188 
3 74 21 6 - 43 144 
4 21 71 11 4 - 107 
5 63 - 10 5 - 78 
6 22 - 7 39 - 68 
7 35 - 17 16 - 68 
8 - 23 - 24 - 47 
9 27 - - 7 - 34 
10 24 - - 2 - 26 
Total participants 546 332 141 133 49 1201 
Total setting type  9 5 6 8 2 
 
 a Includes participants vaccinated in LHD clinics other than STD and family planning 
 
 
Supplementary Table 2.2. Frequency and percentage of doses received by WV Pilot Project 
setting type  
*Those receiving dose one who received dose two, **those receiving dose one who received 
dose three. Abbreviations: STD =sexually transmitted disease; LHD = local health department. 
a Includes participants vaccinated in LHD clinics other than STD and family planning 
 







LHD - STD clinic (n=9) 546 314 (57.5) 189 (34.6)  
LHD outreach to substance use 
treatment center (n=5) 
332 239 (72.0) 138 (41.6)  
LHD outreach to correctional  
facility (n=6) 
141 114 (80.9) 45 (31.9)  
LHD – other clinica (n=8) 133 64 (48.1) 29 (21.8)  
LHD - family planning clinic (n=2) 49 42 (85.7) 31 (63.3)  




Supplementary Table 2.3. Mixed-effects model adjusted odds ratios controlling for local health 
department as a random effect  
 Primary outcome Secondary outcome  
Received 3 doses Received at least 2 doses 
Variable aOR 95% CI p-value aOR 95% CI p-value 
Setting type 
     
LHD - STD clinic 1 
     
LHD outreach to 
substance use treatment 
center 
1.73 (1.20-2.50) 0.006 2.12 (1.46-3.09) <0.001 
LHD outreach to 
correctional  
facility  
0.93 (0.57-1.50) 0.737 2.94 (1.74-4.96) <0.001 
LHD - other clinica 0.56 (0.30-1.01) 0.054 0.74 (0.44-1.23) 0.221 
LHD - family planning 
clinic 
3.51 (1.63-7.56) 0.003 4.88 (1.87-12.72) 0.003 
       
Sex 
      
Male 1 
     
Female 1.32 (0.97-1.81) 0.075 1.51 (1.11-2.06) 0.014        
Age 
      
18-29 yrs 1 
     
30-39 yrs 1.50 (1.09-2.07) 0.015 1.31 (0.96-1.79) 0.086 
40-49 yrs 2.64 (1.74-4.00) <0.001 1.45 (0.95-2.22) 0.084 
50+ 3.23 (2.03-5.14) <0.001 1.88 (1.18-3.01) 0.01        
Race 
      




African American 1.01 (0.63-1.61) 0.971 0.82 (0.53-1.28) 0.389 
 Abbreviations: STD =sexually transmitted disease; LHD = local health department. 
a Includes participants vaccinated in LHD clinics other than STD and family planning 












Factors Associated with Hepatitis B Exposure among People who Report Using 
Methamphetamine: NHANES 2009-2016 
 
Tressler SR, Kushner T, Bhandari R. Factors Associated With Hepatitis B Exposure Among 
People Who Report Using Methamphetamine: National Health and Nutrition Examination 
Survey 2009–2016, J Infect Dis 2020; 221(2):243–250. 
 
ABSTRACT 
Background: With the nation’s focus on the opioid crisis, methamphetamine has made a 
comeback, potentially increasing risk for hepatitis B. We examined factors associated with 
hepatitis B virus (HBV) exposure among people who reported ever using methamphetamine in a 
nationally representative survey. 
Methods: We utilized the National Health and Nutrition Examination Survey to examine factors 
associated with HBV exposure among participants who reported ever using methamphetamine 
using bivariate and multivariable logistic regression. 
Results: Overall, 847 participants met the study inclusion criteria. In multivariable logistic 
regression, female sex (aOR 3.83, 95% CI 1.65 – 8.90), living below the poverty threshold (aOR 
3.17, 95% CI 1.39 – 7.21), injection drug use (IDU) (aOR 4.89, 95% CI 1.95 – 12.26), active 
hepatitis C (HCV) infection (aOR 3.39, 95% CI 1.10 – 12.26), and identifying as men who have 
sex with men (aOR 28.21, 95% CI 5.19 – 153.38) were significantly associated with HBV 
exposure. 
Conclusions: The odds of HBV exposure for females who reported using methamphetamine was 
four times higher than males. Poverty, IDU, and HCV infection were also associated. As 
methamphetamine use increases, it is critical to identify those at risk of acquiring HBV 
infections in order to target testing and vaccination. 








Hepatitis B is a significant public health problem worldwide with over 350 million chronic 
carriers globally, and an estimated 850,000 to 2.2 million individuals in the U.S. [1-3]. Although 
the leading cause of chronic infection worldwide is through vertical transmission, in the U.S., the 
most common mode of transmission is horizontal. Hepatitis B virus (HBV) is spread through 
contact with blood and body fluids and is highly infectious. Acute infection can progress to 
lifelong chronic infection with younger age at time of transmission being the greatest factor in 
progression to chronicity [4]. About 50% of people chronically infected are unaware of their 
infection and remain a source of ongoing transmission [5].  
In the U.S., the incidence of acute hepatitis B infections has decreased 75% over the past three 
decades largely due to the implementation of universal vaccination of infants at birth in 1991 and 
the recommendation for catch-up vaccination of adolescents in 1997 [6, 7]. Due in part to low 
rates of hepatitis B nationwide, attention has centered on transmission and prevention of HIV 
and HCV in high-risk groups. As recently as 2006, the rate of acute HBV infections in the U.S. 
has remained stable at around 1 case per 100,000 people [8]. However, over the past decade, 
opioid misuse and injection drug use (IDU) has resulted in a resurgence in cases of acute 
hepatitis B [9, 10].  
Nationwide, in 2015 the highest incidence of acute HBV infections occurred among persons 30 
to 39 years of age with 30% of newly infected people reporting IDU as a risk factor [11]. Most 
notably, there was a substantial increase in acute HBV cases in parts of Appalachia including 
Kentucky, Tennessee, and West Virginia. From 2009-2013, there was a 114% increase in the 
number of newly reported acute infections in these three states [8]. The majority of the cases 
occurred among non-Hispanic whites, 30 to 39 years of age with 75% reporting IDU as a risk 
factor [8]. 
With the nation’s focus on the opioid crisis, methamphetamine has made a largely unnoticed 
comeback. Methamphetamine use in the U.S. peaked around 2005 but has reemerged as a threat 
in recent years accounting for 11% of overdose deaths in 2016 [12, 13]. Nationwide use has 




use almost doubled from 18.8% in 2011 to 34.2% among people using opioids who sought 
treatment in the U.S. in 2017 [14]. The increase in methamphetamine use and co-use with 
opioids represents a public health threat requiring a refocusing of response efforts.  
Methamphetamine is a potent stimulant that can be smoked, injected, snorted, or taken orally 
[15]. People who use methamphetamine either through injection or non-injection routes are at an 
increased risk for acquiring sexually transmitted infections including hepatitis B [15]. For people 
who inject methamphetamine, HBV can be acquired through sharing of needles as well as 
injecting equipment, and sexual practices. Outbreaks of hepatitis B among people who inject 
methamphetamine have been documented [16, 17]. A study by Vogt et al. (2006) found an 
association between sharing equipment used to inject methamphetamine, including rinse water 
and cotton filters, and HBV infection [16]. More recently, methamphetamine has been 
implicated in a ten-fold increase in acute hepatitis B cases, as well as an increase in hepatitis C, 
HIV, and syphilis in Winnipeg, Canada [18].  
Hepatitis B remains a real and ongoing threat to a number of high-risk groups, including people 
who use drugs and those engaging in high-risk sexual behaviors. It is recommended that high-
risk people without serological evidence of HBV infection or immunity be vaccinated against 
HBV [10]. As methamphetamine use and co-use with opioids increase, it is important to 
understand the risk factors associated with HBV exposure among this population to help guide 
education, testing, and vaccination efforts.  
In this study, we examined factors associated with hepatitis B exposure among people who 
reported ever using methamphetamine in the National Health and Nutrition Examination Survey 
(NHANES) [19]. 
METHODS 
The study population included NHANES participants who answered “yes” to ever using 
cocaine/heroin/methamphetamine, and subsequently “yes” to using methamphetamine from 2009 
to 2016 and completed testing for HBV. Participants under the age of 18 and older than 69 were 
not eligible to answer this question and were excluded from this study. Participants with 
serological evidence of HBV immunity from vaccination were also excluded from the study (see 





NHANES is a cross-sectional survey conducted by the Centers for Disease Control and 
Prevention’s (CDC) National Center for Health Statistics (NCHS) to assess health and nutritional 
status of the U.S. population [19]. Data are collected over a two-year period and include 
participant interviews accompanied by physical examinations and laboratory specimen 
collection. Participants are selected using a complex, multistage, probability sampling design that 
is representative of U.S. noninstitutionalized civilian population living in the 50 states and the 
District of Columbia. NHANES data are publicly available for research purposes.  
Outcome variable 
The outcome variable, exposure to HBV, was defined as a positive result to total hepatitis B core 
antibody (anti-HBc), a marker of past or present infection with hepatitis B. Susceptibility to 
HBV was defined as being negative for all HBV lab markers including anti-HBc, hepatitis B 
surface antigen (HBsAg), and hepatitis B surface antibody (HBsAb). Participants with 
serological evidence of vaccine-induced immunity, defined as being solely HBsAb positive, 
were excluded. 
Exposure variables   
Exposure variables known to be associated with hepatitis B exposure were chosen based on 
previous studies and availability in the NHANES dataset. For the frequency of 
methamphetamine use and questions on sexual identity and partners, only participants 18 to 59 
years old were eligible to answer. Classifications for each variable can be found in Table 3.1. 
Hepatitis C status was coded as positive, negative, or missing. Negative was defined as antibody 
negative, or antibody positive but subsequently testing RNA negative. Positive was defined as 
confirmed to be RNA positive after a positive antibody test indicating an active HCV infection. 
Lab markers for HIV, HSV 2, and syphilis were not included due to small sample size and 
inability to combine due to differences in age groups tested. Indeterminate lab results were coded 





SAS version 9.4 was used for all analyses. Survey procedures including SURVEYFREQ and 
SURVEYLOGISTIC were used to account for complex survey design in the analysis. 
SDMVSTRA was used in the strata statements and SDMVPSU in the cluster statements. 
Weighted frequencies and standard errors for the combined eight years of data were calculated 
by multiplying the sample weight WTMEC2YR by 1/4. A subcategory including only 
participants who completed the medical exam and answered ‘yes’ to ever using 
methamphetamine was included at the beginning of each table statement when calculating 
frequencies and in the domain statement for logistic regression. For all analyses, confidence 
intervals (CI) that did not cross one and a p-value less than .05 were considered statistically 
significant.   
Descriptive statistics, weighted percentages, and weighted frequencies were calculated for all 
variables. The Rao Scott Chi-squared statistic was calculated to assess the relationship between 
each exposure variable and HBV exposure. Bivariate logistic regression was used to calculate the 
unadjusted odds ratio (uOR) and 95% CI for each exposure variable and HBV exposure. Three 
multivariable logistic regression models were used to calculate the adjusted odds ratios (aOR) 
and 95% CI for the exposure variables and HBV exposure. Model 1 examined the association of 
demographic variables (sex, age, and race/ethnicity) with the outcome among participants 18-69 
years. Model 2 built on Model 1 and examined the association of poverty index, health 
insurance, IDU, and HCV status in addition to the demographic variables in Model 1 among 
participants 18-69 years. Model 3 adjusted for all exposure variables but only included 
participants 20 to 59 years old due to age restriction for answering the following questions: 
education (20 years and older), number of times used methamphetamine (18 to 59 years old), 
sexual identity (18 to 59 years old), and number of sex partners in the past year (18 to 59 years 
old). A missing category was created for each exposure variable with missing data and was 
included in the analyses.  
A sensitivity analysis was performed on missing values for question DUQ240 – Have you ever 






A total of 40,439 people participated in NHANES from 2009 through 2016. Out of the total 
participants who reported ever using methamphetamine and completed HBV testing, 5.6% were 
exposed to HBV, 15.1% had vaccine-induced immunity, and almost 80% were susceptible to 
HBV infection. Of those exposed to HBV, 6.4% were HBsAg positive indicating an active 
hepatitis B infection. After excluding those with vaccine-induced immunity, 6.6% of participants 
who reported ever using methamphetamine had lab markers consistent with HBV exposure and 
93.4% were susceptible to HBV infection. Overall, 847 participants reported ever using 
methamphetamine and were either exposed or susceptible to hepatitis B and thus eligible for 
inclusion in the study (see Figure 3.1).  
Frequencies and weighted estimates for exposure variables and the HBV exposure can be found 
in Table 3.1. Based on the weighted estimate, the 847 participants represented approximately 
11,048,115 people in the U.S. All reported percent estimates and standard errors are calculated 
from the weighted frequencies.  
In the study sample, the majority of participants were male (68.3%) and approximately, three-
quarters of participants were between 30 to 59 years of age, with the greatest proportion in the 50 
to 59 age range (30.8%). Most participants were non-Hispanic white (77.5%) and living at or 
above twice the poverty index (58.6%). While only 15% of participants were categorized as 
living below the poverty index threshold, they comprised over one-third of those exposed to 
HBV (35.4%). Nearly three-quarters of participants reported having some type of health 
insurance (73.1%) and education attainment as high school, GED, or higher. About a fifth 
reported ever injecting drugs (20.2%) but they accounted for over half of those exposed to HBV 
(56.7%). While only 7% had an active HCV infection they accounted for 28.5% of those exposed 
to HBV. Almost an equal number of participants reported using methamphetamine ≤ to 5 times, 
6 to 49 times, and ≥ 50 times. Of those exposed to HBV 42.5% reported using methamphetamine 
≥ 50 times. The majority of participants self-identified as heterosexual (80.7%) and reported less 
than 2 sexual partners in the past year (65.8%). 
Table 3.2 presents the unadjusted odds ratios (uOR) and 95% CIs for each exposure variable and 
the outcome variable. Among those who reported using methamphetamine, being female was 
significantly associated with exposure to HBV (uOR 2.11, 95% CI 1.05 - 4.26), as was being 




3.73, 95% CI 1.93 – 7.21), IDU (uOR 6.28, 95% CI 2.77- 14.26), active HCV infection (uOR 
7.07, 95% CI 3.24 – 15.44), using methamphetamine ≥ 50 times (5.01, 95% CI 1.88 – 13.35), 
and identifying as MSM (uOR 6.33, 95% CI 1.81 – 22.14).  
Adjusted odds ratios (aOR) and 95% CIs were calculated in models 1, 2, and 3. The results of 
each model can be found in Table 3.2. After controlling for sex, age, and race/ethnicity in model 
1, being female (aOR 2.18, 95% CI 1.06 – 4.51) and non-Hispanic black (aOR 2.37, 95% CI 
1.09 – 2.31) were significantly associated with exposure to HBV. After adding poverty index, 
health insurance, IDU, and HCV status, there was a significant association between being female 
(aOR 2.54, 95% CI 1.27 – 5.07), 60 to 69 years old (5.67, 95% CI 1.04 – 30.96), living below the 
poverty threshold (aOR 3.14, 95% CI 1.47 – 6.74), IDU (aOR 4.82, 95% CI 2.05 – 11.31), and 
active HCV infection (aOR 2.85, 95% CI 1.05 – 7.78). In model 3, after adjusting for all 
exposure variables there was a significant association between being female (aOR 3.83, 95% CI 
1.65 – 8.90) and exposure to HBV, as well as living below the poverty threshold (aOR 3.17, 95% 
CI 1.39 – 7.21), IDU (aOR 4.89, 95% CI 1.95 – 12.26), active HCV infection (aOR 3.39, 95% CI 
1.10 – 12.26), and identifying as MSM (aOR 28.21, 95% CI 5.19 – 153.38).  
To answer methamphetamine specific questions, participants had to answer ‘yes’ to ever using 
cocaine, heroin, or methamphetamine. Missing data for this inclusion question were examined. 
Among all participants, 19,998 were eligible to answer the question and data were missing for 
2,587 (12.9%) participants. The odds of missing values were higher for females, younger 
participants, non-Hispanic blacks, and other races. All odds ratios indicated weak associations 
between missing values and the demographic variables. Based on these findings selection bias 
did not appear to be a factor. 
DISCUSSION 
In this study, eight years of NHANES data were evaluated in order to provide estimates of the 
U.S. non-institutionalized population representing over 11 million people who reported ever 
using methamphetamine. The use of lab markers provided accurate estimates of hepatitis B 
exposure and hepatitis C infection in this population. Compared to the overall study population 
who reported ever using methamphetamine, a disproportionate amount of the HBV exposed 
group comprised of females, persons with active HCV infection, MSM, participants 50 to 69 




IDU. In bivariate analysis, the odds of HBV exposure among those who reported using 
methamphetamine ≥ 50 times was five times higher compared to those who used ≤ 5 times, 
suggesting an increased odds of exposure with increased use. In the full model, four of the 
significant associations were consistent with previously identified risk factors for acquiring 
hepatitis B infection, including living below the poverty threshold, IDU, active HCV infection, 
and self-identifying as MSM [4, 20]. Also, being female was significantly associated with HBV 
exposure. After adjusting for all co-variates, the odds of hepatitis B exposure for females who 
reported using methamphetamine was nearly four times higher compared to males. Interestingly, 
in this study, reporting multiple sexual partners was not associated with hepatitis B exposure. 
This result was unexpected considering high-risk sexual practices, including multiple sexual 
partners, is associated with both methamphetamine use and hepatitis B infection. However, while 
methamphetamine use was reported as ever having used in lifetime, the number of sexual 
partners was only reported for the previous year. 
Nationwide, an increase in HCV infection among reproductive age women and a rise in babies 
born with neonatal abstinence syndrome indicates increased drug use among women in general 
[21, 22]. In light of the 2019 MMWR study highlighting the increase in methamphetamine use 
among females with primary and secondary syphilis, the results from this study suggest a similar 
pattern for HBV exposure in females using methamphetamine [23]. Additionally, a study 
analyzing hospital delivery data from 2004 to 2015 found an increasing trend of amphetamine 
use among women delivering a baby; amphetamine use was reported in 2.4 per 1,000 hospital 
deliveries in 2014 to 2015 [24].  
Some of the exposures identified in this study were consistent with previous studies; however, 
the significant association between females who reported methamphetamine use and HBV 
exposure suggests increased efforts may be needed for this population subgroup. These findings 
highlight the importance of screening for substance use including methamphetamine, as well as 
testing and vaccinating for HBV among reproductive-age women to prevent mother-to-child 
transmission of HBV during pregnancy. The U.S. Preventive Services Task Force recently 
reaffirmed their recommendation that all pregnant women be screened for HBV at the first 
prenatal visit highlighting the important role of obstetrician-gynecologists in providing primary 




provide another avenue to reach high-risk individuals, including women, who may not access 
primary care services.  
NHANES is a cross-sectional study design and temporality between risk factors and HBV 
exposure cannot be established. It is not possible to know if HBV exposure occurred as a result 
of methamphetamine use or if use is a potential marker for other high-risk behaviors. 
Additionally, a relatively small sample size and subcategories used in analyses resulted in a 
number of wide confidence intervals and these results should be interpreted with caution. 
Participants were included in the study if they reported ‘ever using’ methamphetamine. The 
sensitive nature of questions regarding drug use and sexual behavior may result in people not 
answering certain questions or not answering accurately resulting in incorrect estimates arising 
from potential non-response or misclassification bias. However, these questions were self-
administered using an Audio Computer-Assisted Self Interview system in a private room during 
the medical exam component of the survey, which may have resulted in participants feeling more 
comfortable to respond truthfully. Finally, susceptibility to HBV was determined as the absence 
of all HBV lab markers, including anti-HBs. In vaccinated persons, anti-HBs wanes over time, 
therefore some participants included in the susceptible comparison group may have vaccine-
induced immunity with anti-HBs levels below detectable levels. NHANES data do not include 
incarcerated or homeless individuals; this may affect the generalizability of results to the entire 
U.S. population. 
CONCLUSION 
As methamphetamine use continues to rise, it is important to identify those at highest risk of 
acquiring hepatitis B infections in order to target testing and vaccination programs. The 
estimated number of susceptible participants who reported using methamphetamine in this study 
suggests a need to provide targeted vaccination efforts in this potentially at-risk population. 
Harm reduction programs should incorporate testing for HBV and vaccination to help reduce the 
disease burden among this high-risk group.  Additionally, the results from this study indicates a 
need to target not only high-risk individuals but also older individuals who may not have 
benefited from the HBV birth dose or adolescent catch-up vaccination. Finally, the association of 
HBV exposure with active HCV infection suggests shared risk factors and efforts for HBV 
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Table 3.1 Descriptive statitics, weighted percents, weighted frequencies, and standard errors for exposure variables and HBV status 
 All subjects Exposed to HBV Susceptible to HBV  









N 847 11,048,115 
(752,495) 
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Missing 8 63,252 (29,626) 0.57 
(0.27) 
0 N/A 8 0.61 
(0.28) 
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*p-value for Rao-Scott Chi-squared test statistic 




Table 3.2 Unadjusted and adjusted odds ratios for association between exposure variables and 
HBV status 
  Model 1* Model 2 † Model 3 ‡ 
(ages 20 to 59) 









    
Male 1 1 1 1 
Female 2.11 
(1.05 - 4.26) 
2.18 
(1.06 - 4.51) 
2.54 
(1.27 - 5.07) 
3.83 
(1.65 - 8.90) 
Age 
    
18-29 yrs 1 1 1 1 
30-39 yrs 0.67 
(0.12 – 3.72) 
0.72 
(0.13 - 3.90) 
0.89 
(0.17 - 4.77) 
0.83  
(0.10 - 6.80) 
40-49 yrs 0.676 
(0.13 - 3.66) 
0.73 
(0.13 - 3.96) 
0.55 
(0.10 0 3.03) 
0.50 
(0.07 - 3.67) 
50-59 yrs 1.95 
(0.39 - 9.60) 
2.02 
(0.39 - 10.60) 
1.78 
(0.38 - 8.42) 
1.79 
(0.23 - 13.95) 
60-69 yrs 3.77 
(0.76-18.72) 
4.02 
(0.80 - 20.30) 
5.67 
(1.04 - 30.96) 
NA 
Race or ethnicity  
    
Non-Hispanic White 1 1 1 1 
Non-Hispanic Black 2.63 
(1.30 - 5.30) 
2.37 
(1.09 - 5.14) 
1.53 
(0.52 - 4.53) 
1.99 
(0.52 - 7.67) 
Hispanic/Other 0.786 
(0.41 - 1.52) 
1.17 
(0.59 - 2.31) 
1.01 
(0.49 - 2.10) 
0.97 
(0.44 - 2.14) 
Poverty Index 
    
     Below threshold 3.73 
(1.93 - 7.21) 
 
3.14  
(1.47 - 6.74) 
3.17 
(1.39 - 7.21) 
     1 to 1.9 1.06 
(0.39 - 2.63) 
 
0.98 
(0.34 - 2.87) 
0.99 
(0.32 -3.06) 
     ≥ 2.0 1 
 
1 1 
Health Insurance  
    
     Yes 1 
 
1 1 
     No 1.14 
(0.53 - 2.45) 
 
1.22 
(0.46 - 3.22) 
1.58 
(0.61 - 4.01) 
Injection Drug Use 





(2.77 - 14.26) 
 
4.82 
(2.05 - 11.31) 
4.89 
(1.95 - 12.26) 
HCV 





(3.24 - 15.44) 
 
2.85 
(1.05 - 7.78) 
3.39 
(1.10 - 12.26) 
Education (20+ yrs) 
    






     ≥ 12 H.S. or GED 1.10 
(0.46 - 2.60) 
  
1.39 
(0.31 - 6.34) 
Number or times used 
(18-59 yrs) 
    
     ≤ 5 times 1 
  
1 
     6-49 times 2.13 
(0.78 - 5.79) 
  
1.65 
(0.54 - 5.06) 
     ≥ 50 times 5.011 
(1.88 - 13.35) 
  
2.78 
(0.67 - 11.47) 
Sexual Identity  
(18-59 yrs) 





(1.81 - 22.14) 
  
28.21 
(5.19 - 153.38) 
Other  1.24 
(0.33 - 4.71) 
  
0.55 
(0.07 - 4.41) 
Sex Partners in Past Year 
(18-59 yrs) 
    
     < 2 1 
  
1 
     ≥ 2 1.262 
(0.53 - 3.0) 
  
1.19 
(0.35 - 4.06) 
HCV = Hepatitis C virus, HS = High School, GED = General Education Development, MSM = Men who 
have sex with men 
*Model 1 includes sex, age, and race/ethnicity 
†Model 2 includes sex, age, race/ethnicity, poverty index, health insurance, injection drug use, and HCV 
‡Model 3 includes sex, age, race/ethnicity, poverty index, health insurance, injection drug use, HCV, 
















Despite decreasing trends nationwide, WV’s rate of acute hepatitis B increased from 2002 to 
2016, and was 12 times higher than the US rate in 2017 [1]. A safe and effective HBV vaccine 
has existed for almost four decades, yet HBV continues to be problematic in certain at-risk 
groups. Ongoing transmission indicates the need for continual efforts to identify changing 
hepatitis B trends and the necessity to evaluate the effectiveness of vaccine interventions meant 
to reach those most at risk. The specific aims of our three studies were to assess changes in the 
acute hepatitis B in WV over the past decade, evaluate the effectiveness of vaccinating at-risk 
individuals in settings outside LHD STD clinics, and understand factors associated with HBV 
exposure in an emerging at-risk group of people who report using methamphetamine. Notable 
findings of our research include: 
 A shift in the WV county-level hotspot of acute hepatitis B rate over the past decade and 
a significant rate decrease in half of the WV Pilot Project counties after vaccine 
distribution. 
 Increased odds of completing all three doses of hepatitis B vaccine at substance use 
treatment centers and LHD family planning clinics as well as receipt of at least two 
doses at substance use treatment centers, LHD family planning clinics, and correctional 
facilities compared to WV Pilot Project participants vaccinated through LHD STD 
clinics. 
 Higher odds of HBV exposure among women who reported using methamphetamine, as 
well as those living below the poverty threshold, people with active HCV infection, men 
identifying as MSM, or self-identifying as a person who injects drugs [2]. 
Results from our geospatial analyses can help identify areas in current need of enhanced hepatitis 
B surveillance and guide placement of harm reduction services including HBV testing and 
vaccination. However, ongoing geospatial analyses are needed to visualize and monitor trends 
over time and test for statistically significant hotspots of HBV transmission. Additionally, unique 
approaches, including Bland-Altman analysis and graphing, provide a way to evaluate HBV 
prevention efforts at the county-level by visualizing significant rate differences in relation to the 




In addition to monitoring trends in county-level data, evaluation of participant-level data is key 
to understanding successful aspects of vaccination programs in at-risk group. For our WV Pilot 
Project participant study, data were available for over half of the LHDs representing 1,201 
participants. While most participants were vaccinated through LHD STD clinics, there were 
increased odds of receiving all three doses if vaccinated through substance use treatment centers 
or LHD family planning clinics. Given that IDU and street drug use are the two most commonly 
reported risk factors among persons with acute HBV infection in WV, our findings indicate 
vaccination services provided through partnerships between LHDs and substance use treatment 
centers may result in more at-risk adults both receiving and completing the HBV series [3, 4]. 
Study results also indicate there were increased odds of receiving at least two doses at substance 
use treatment centers, LHD family planning clinics, and correctional facilities. In 2016, 
incarceration was the third most common risk factor among people with acute HBV infection 
[4]. Regional jails and drug courts are another way LHDs can successfully vaccinate at-risk 
individuals with either two doses of the traditional three-dose HBV series or both doses of the 
new highly immunogenic Heplisav-B vaccine.  
Finally, our findings indicate that people reporting methamphetamine use in a nationally 
representative survey of the noninstitutionalized population, have similar factors associated with 
HBV exposure as those previously identified including identifying as MSM, active HCV 
infection, living below the poverty threshold, and IDU [5-7]. Based on these results, vaccination 
efforts can potentially reach those at-risk by targeting groups already known to have an increased 
risk of exposure. However, a notable finding of our study was the odds of HBV exposure was 
four times higher in women who reported using methamphetamine compared to men. These 
findings coupled with increases in HCV infections and HBV exposure among women of 
childbearing age highlight the need to provide testing and vaccination to women [8-11]. Results 
from the WV Pilot Project indicate that LHD family planning clinics can serve as an important 
way to reach women and ensure they complete the HBV vaccine series thus protecting them and 
future generations.  
Despite the availability of a safe and effective hepatitis B vaccine, many individuals remain at 




and substance misuse. Ongoing efforts are needed to identify trends, guide testing and 
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